Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans.
Journal
Federal practitioner : for the health care professionals of the VA, DoD, and PHS
ISSN: 1078-4497
Titre abrégé: Fed Pract
Pays: United States
ID NLM: 9500574
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
entrez:
9
2
2022
pubmed:
10
2
2022
medline:
10
2
2022
Statut:
ppublish
Résumé
Since 1987, statin therapy has been the mainstay of treatment for hypercholesterolemia, and current practice guidelines recommend statins as first-line therapy given demonstrated reductions in elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) mortality reduction in robust clinical trials. The primary objective of this case series was to assess LDL-C reduction associated with alirocumab use in statin-intolerant veterans at a single US Department of Veterans Affairs medical center. The secondary objective was to assess the incidence of CV events. A retrospective chart review was conducted to identify statin-intolerant veterans who were initiated on treatment with alirocumab for LDL-C and/or CV risk reduction between June 2017 and May 2019. Electronic health records of all eligible patients who received alirocumab were reviewed, and basic demographics (patient age, sex, and race/ethnicity) as well as medical characteristics at baseline were collected. Baseline LDL-C was compared with levels at 4 and 24 weeks. Although a majority of patients saw a significant and clinically meaningful reduction in LDL-C, the group of patients with an increase in LDL-C may have benefitted from targeted intervention to improve medication and dietary adherence. Alirocumab use in 24 statin-intolerant veterans resulted in a significant reduction in LDL-C at 4 and 24 weeks after initiation. Large long-term studies would better evaluate CV benefit associated with alirocumab therapy in a veteran population.
Sections du résumé
BACKGROUND
BACKGROUND
Since 1987, statin therapy has been the mainstay of treatment for hypercholesterolemia, and current practice guidelines recommend statins as first-line therapy given demonstrated reductions in elevated low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) mortality reduction in robust clinical trials. The primary objective of this case series was to assess LDL-C reduction associated with alirocumab use in statin-intolerant veterans at a single US Department of Veterans Affairs medical center. The secondary objective was to assess the incidence of CV events.
METHODS
METHODS
A retrospective chart review was conducted to identify statin-intolerant veterans who were initiated on treatment with alirocumab for LDL-C and/or CV risk reduction between June 2017 and May 2019. Electronic health records of all eligible patients who received alirocumab were reviewed, and basic demographics (patient age, sex, and race/ethnicity) as well as medical characteristics at baseline were collected. Baseline LDL-C was compared with levels at 4 and 24 weeks.
RESULTS
RESULTS
Although a majority of patients saw a significant and clinically meaningful reduction in LDL-C, the group of patients with an increase in LDL-C may have benefitted from targeted intervention to improve medication and dietary adherence.
CONCLUSIONS
CONCLUSIONS
Alirocumab use in 24 statin-intolerant veterans resulted in a significant reduction in LDL-C at 4 and 24 weeks after initiation. Large long-term studies would better evaluate CV benefit associated with alirocumab therapy in a veteran population.
Identifiants
pubmed: 35136343
doi: 10.12788/fp.0176
pii: fp-38-11s-e67
pmc: PMC8820199
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e67-e71Informations de copyright
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.
Déclaration de conflit d'intérêts
Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.
Références
Heart Views. 2011 Jul;12(3):121-7
pubmed: 22567201
Am J Cardiovasc Drugs. 2018 Jun;18(3):157-173
pubmed: 29318532
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):123-6
pubmed: 27668059
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
N Engl J Med. 2018 Nov 29;379(22):2097-2107
pubmed: 30403574
Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45
pubmed: 24222016
Ann Intern Med. 2018 Mar 6;168(5):376-379
pubmed: 29181527
J Am Heart Assoc. 2019 Apr 2;8(7):e011662
pubmed: 30922146
J Clin Lipidol. 2015 Nov-Dec;9(6):758-769
pubmed: 26687696
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391